アブストラクト
| Title | 肝硬変の合併症対策 |
|---|---|
| Subtitle | 今月のテーマ (総説) 新しい肝硬変診療 〜ガイドライン2020を紐解く〜 |
| Authors | 徳本良雄, 日浅陽一1) |
| Authors (kana) | |
| Organization | 1)愛媛大学大学院消化器・内分泌・代謝内科学 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 118 |
| Number | 1 |
| Page | 30-40 |
| Year/Month | 2021 / 1 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨:肝硬変の診療にあたっては門脈圧亢進症, 腹水, 肝性脳症など多彩な合併症の適切な管理が生命予後の改善に直結する. わが国では腹水や肝性脳症に対する新規薬剤が使用可能となり治療選択肢が広がることで, 肝硬変の合併症に対する治療戦略に大きな変化がみられている. 一方で, 肝硬変の合併症は多岐にわたり, サルコペニアや門脈肺高血圧症などのさらなる病態解明や治療法の開発が望まれる. 本稿では肝硬変の合併症対策についてのクリニカルクエスチョンに対する回答として, 新ガイドラインの考え方と今後の課題について概説する. |
| Practice | 臨床医学：内科系 |
| Keywords | 門脈圧亢進症, 腹水, 肝腎症候群, 肝性脳症, サルコペニア |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 日本消化器病学会: 肝硬変診療ガイドライン2015(改訂第2版), 南江堂, 2015
- 2) 日本消化器病学会: 肝硬変診療ガイドライン 2020, 2020
- 3) Kerbert AJ, Chiang FW, van der Werf M, et al: Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol 29; 380-387: 2017
- 4) Li L, Yu C, Li Y: Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol 25: 147-155: 2011
- 5) Wells M, Chande N, Adams P, et al: Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 35; 1267-1278: 2012
残りの32件を表示する
- 6) Deshpande A, Pasupuleti V, Thota P, et al: Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol 28; 235-242: 2013
- 7) Shaheen NJ, Stuart E, Schmitz SM, et al: Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 41; 588-594: 2005
- 8) Hidaka H, Nakazawa T, Wang G, et al: Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial. J Gastroenterol 47; 118-126: 2012
- 9) de Franchis R, Baveno VI Faculty: Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 63; 743-752: 2015
- 10) Garcia-Tsao G Abraldes JG, Berzigotti A, et al: Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65: 310-335: 2017
- 11) European Association for the Study of the Liver: EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69: 406-460: 2018
- 12) Kobayakawa M, Kokubu S, Hirota S, et al: Short-term safety and efficacy of balloon-occluded retrograde transvenous obliteration using ethanolamine oleate: results of a prospective, multicenter, single-arm trial. J Vasc Interv Radiol 28; 1108-1115.e2: 2017
- 13) Mishra SR, Sharma BC, Kumar A, et al: Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol 54; 1161-1167: 2011
- 14) Akahoshi T, Hashizume M, Tomikawa M, et al: Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J Gastroenterol Hepatol 23; 1702-1709: 2008
- 15) Hiramine Y, Uojima H, Nakanishi H, et al: Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol 53; 258-268: 2018
- 16) Mori T, Ohsaki Y, Oba-Yabana I, et al; Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. Hepatol Res 47; 11-22: 2017
- 17) Loomba R, Wesley R, Bain A, et al: Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 7; 487-493: 2009
- 18) Angeli P, Gines P, Wong F, et al: Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 62: 968-974: 2015
- 19) Wong F, O'Leary JG, Reddy KR, et al: New consensus definition for acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 145; 1280-1288.e1: 2013
- 20) Gluud LL, Dam G, Les I, et al: Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 5; CD001939: 2017
- 21) Katayama K, Saito M, Kawaguchi T, et al: Effect of zinc on iiver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial. Nutrition 30; 1409-1414: 2014
- 22) Shiraki M, Shimizu M. Moriwaki H, et al: Carnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patients. Hepatol Res 47; 321-327: 2017
- 23) Tajiri K, Futsukaichi Y, Kobayashi S, et al: L-carnitine for the treatment of overt hepatic encephalopathy in patients with advanced liver cirrhosis. J Nutr Sci Vitaminol 64; 321-328: 2018
- 24) Tsochatzis EA, Senzolo M, Germani G, et al: Systematic review: portal vein thrombosis in cirrhosis. Aliment. Pharmacol Ther 31: 366-374: 2010
- 25) Berry K, Taylor J, Liou IW, et al: Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis. Clin Gastroenterol Hepatol 13; 585-593: 2015
- 26) Nery F, Chevret S, Condat B, et al: Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 61; 660-667: 2015
- 27) Hidaka H, Kokubu S, Sato T, et al: Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial. Hepatol Res 48: E107-E116: 2018
- 28) Nagaoki Y, Aikata H, Daijyo K, et al: Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hcpatol Res 48; 51-58: 2018
- 29) Nishikawa H, Shiraki M, Hiramatsu A, et al: Japan Society of Hepatology guidelines for sarcopenia in liver disease(1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 46; 951-963: 2016
- 30) Iwasa M, Karino Y, Kawaguchi T, et al: Relationship of muscle cramps to quality of life and sleep disturbance in patients with chronic liver diseases: A nationwide study. Liver Int 38; 2309-2316: 2018
- 31) 熊田 卓, 熊田博光, 与芝 真, 他: TJ-68ツムラ芍薬甘草湯の筋痙攣(肝硬変に伴うもの)に対するプラセボ対照二重盲検群間比較試験. 臨床医薬 15; 536-538: 2003
- 32) Nakanishi H, Kurosaki M, Tsuchiya K, et al: L-carnitine reduces muscle cramps in patients with cirrhosis. Clin Gastroenterol Hepatol 13; 1540-1543: 2015
- 33) Hidaka H, Kurosaki M, Tanaka H, et al: Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol 17; 1192-1200: 2019
- 34) Oeda S, Takahashi H, Yoshida H, et al: Prevalence of pruritus in patients with chronic liver disease: A multicenter study. Hepatol Res 48; E252-262; 2018
- 35) Kumada H, Miyakawa H, Muramatsu T, et al: Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial. Hepatol Res 47; 972-982: 2017
- 36) Arguedas MR, Singh H, Faulk DK, et al: Utility of pulse oximetry screening for hepatopulmonary syndrome. Clin Gastroenterol Hepatol 5; 749-754: 2007
- 37) Sitbon O, Bosch J, Cottreel E, et al: Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med 7; 594-604: 2019
